Overview

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Status:
Withdrawn
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene Corporation
Treatments:
Amrubicin
Trastuzumab